Skip to Content

Clinoril Side Effects

Generic Name: sulindac

Note: This page contains information about the side effects of sulindac. Some of the dosage forms included on this document may not apply to the brand name Clinoril.

Common side effects of Clinoril include increased liver enzymes. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to sulindac: oral tablet

In addition to its needed effects, some unwanted effects may be caused by sulindac (the active ingredient contained in Clinoril). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking sulindac:

More common
  • Acid or sour stomach
  • belching
  • constipation
  • headache
  • heartburn
  • nausea or vomiting
  • skin rash
  • stomach pain
Less common
  • Excess air or gas in the stomach or intestines
  • itching skin
  • passing gas
  • stomach cramps
  • swelling
  • weight loss
  • Back or leg pains
  • bleeding gums
  • blistering, peeling, or loosening of the skin
  • bloating
  • bloody or black, tarry stools
  • bloody or cloudy urine
  • blurred or loss of vision
  • burning feeling in the chest or stomach
  • burning while urinating
  • chest pain
  • chills
  • clay-colored stools
  • confusion
  • cough or hoarseness
  • cracks in the skin
  • dark urine
  • decreased urine output
  • diarrhea
  • difficult or labored breathing
  • difficult or painful urination
  • difficulty with swallowing
  • dilated neck veins
  • discoloration of urine
  • disturbed color perception
  • dizziness
  • double vision
  • extreme fatigue
  • eye pain
  • fainting
  • feeling of warmth
  • fever
  • flu-like symptoms
  • general body swelling
  • general feeling of discomfort or illness
  • groin pain
  • halos around lights
  • hives
  • increased sensitivity of the skin to sunlight
  • increased sweating
  • increased thirst
  • indigestion
  • irregular breathing
  • joint or muscle pain
  • large, flat, blue, or purplish patches in the skin
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • loss of appetite
  • loss of heat from the body
  • lower back or side pain
  • muscle aches, pains, or weakness
  • nervousness
  • night blindness
  • noisy breathing
  • nosebleeds
  • numbness or tingling in the hands, feet, or lips
  • overbright appearance of lights
  • painful or difficult urination
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • pale skin
  • persistent bleeding or oozing from puncture sites, mouth, or nose
  • pinpoint red or purple spots on the skin
  • pounding in the ears
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • redness of the face, neck, arms and occasionally, upper chest
  • redness or other discoloration of the skin
  • redness, swelling, or soreness of the tongue
  • scaly skin
  • seizures
  • severe or continuing stomach pain
  • severe sunburn
  • shortness of breath
  • slow or fast, irregular, pounding, or racing heartbeat or pulse
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • stiff neck or back
  • stomach upset
  • swelling of the face, fingers, feet, or lower legs
  • swelling or inflammation of the mouth
  • swollen or painful glands
  • tenderness in the stomach area
  • tightness in the chest
  • troubled breathing
  • tunnel vision
  • unpleasant breath odor
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • upper right abdominal pain
  • vomiting of blood or material that looks like coffee grounds
  • watery or bloody diarrhea
  • weakness or heaviness of the legs
  • weight gain
  • wheezing
  • yellow eyes or skin

If any of the following symptoms of overdose occur while taking sulindac, get emergency help immediately:

Symptoms of overdose
  • Change in consciousness
  • decreased awareness or responsiveness
  • loss of consciousness
  • severe sleepiness

Some of the side effects that can occur with sulindac may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Continuing ringing or buzzing or other unexplained noise in the ears
  • hearing loss
  • Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • burning, dry, or itching eyes
  • decreased hearing
  • difficulty with moving
  • discharge, excessive tearing
  • discouragement
  • false sense of well-being
  • feeling of constant movement of self or surroundings
  • feeling sad or empty
  • hair loss or thinning of the hair
  • hallucinations
  • irritability
  • loss of interest or pleasure
  • metallic or bitter taste
  • mood swings
  • muscle cramping or stiffness
  • personality changes
  • redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
  • restlessness
  • sensation of spinning
  • sleepiness or unusual drowsiness
  • sleeplessness
  • sore or dry mucous membranes
  • swelling or redness in the joints
  • trouble with concentrating
  • trouble with sleeping
  • unable to sleep
  • vaginal bleeding

For Healthcare Professionals

Applies to sulindac: compounding powder, oral tablet


Pancreatitis is a rare, but potentially severe, dose-independent side effect of sulindac (the active ingredient contained in Clinoril) The majority of cases present within the first six months of therapy, although onset after five years of sulindac therapy is reported in at least one case.

Severe odynophagia secondary to sulindac-induced esophageal ulceration has been reported.

Patients with a history of serious gastrointestinal events or alcohol abuse are at increased risk for severe gastrointestinal side effects. Sulindac should be used with caution in these patients.[Ref]

Gastrointestinal (GI) side effects have included dyspepsia, nausea, diarrhea, constipation, flatulence, and occult GI blood loss. More serious GI side effects have included gastritis, gastroenteritis, colitis, esophageal ulcer, peptic ulcer with or without perforation, GI hemorrhage, colonic diaphragms, and pancreatitis. Severe odynophagia secondary to sulindac-induced esophageal ulceration has also been reported. GI events have been fatal in some cases.[Ref]


Hepatic side effects have included elevations in liver function tests in up to 15% of patients. Jaundice, hepatitis (hepatocellular, cholestatic, and mixed-type), cholangitis, and hepatic failure have been reported. One case of drug-associated cholelithiasis has also been reported.[Ref]

Elevations in liver function tests three times normal values occur in less than 1% of patients.

Significant hepatotoxicity has been reported in association with sulindac therapy and is sometimes fatal. While one review found a possible increased incidence in hepatotoxicity in females, in the elderly, and in patients with autoimmune connective tissue disorders, more severe hepatic reactions should be ruled out in any patient with significant or prolonged elevations in liver function tests or other signs and symptoms suggestive of liver injury.[Ref]


Hypersensitivity side effects have rarely included fever, rash, bronchial asthma, dyspnea, and anaphylaxis. In addition, hypersensitivity has been implicated in cases of hepatotoxicity, renal toxicity, pneumonitis, vasculitis, and generalized multiorgan reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Hypersensitivity syndrome has also been reported.[Ref]

One manufacturer described a potentially fatal hypersensitivity syndrome associated with sulindac. Symptoms included fever, chills, diaphoresis, flushing, rash, conjunctivitis, elevations in liver function tests, hepatic failure, jaundice, pancreatitis, pneumonitis, blood dyscrasias, disseminated intravascular coagulation, and renal failure. Other findings included malaise, arthralgia, myalgia, fatigue, hypotension, tachycardia, and chest pain.

Sulindac should be promptly discontinued if fever, pruritus, rash, elevations in liver function tests accompanied by fever, or other hypersensitivity response occurs.[Ref]


The development of anemia may indicate occult gastrointestinal blood loss secondary to gastric irritation or gastrointestinal ulceration.

Thrombocytopenia appears to be secondary to peripheral destruction due to the development of an antiplatelet antibody. Hemolytic anemia also appears to be due to peripheral destruction secondary to the development of an autoantibody.[Ref]

Hematologic side effects have included platelet dysfunction, resulting in increased bleeding times as well as thrombocytopenia, anemia, neutropenia, leukopenia, agranulocytosis, aplastic anemia, and immune hemolytic anemia.[Ref]


Other nonsteroidal anti-inflammatory agents (NSAIDs) may impair the ability of the kidney to cope with low renal blood flow states due to inhibition of prostaglandin-dependent afferent arteriolar vasodilation. Sulindac (the active ingredient contained in Clinoril) may have the same effect. Hence, renal function may be further compromised in patients with heart failure, hypovolemia, cirrhosis, nephrotic syndrome, or hypoalbuminemia. Additional risk factors for NSAID-induced renal insufficiency are advanced age and concomitant use of diuretics.

A case-control study suggested that patients who consumed 5000 or more pills containing NSAIDs during their lifetime may be at increased risk of end-stage renal disease.[Ref]

Renal side effects have included acute renal failure secondary to membranous glomerulonephritis and interstitial nephritis, as well as nephrotic syndrome (despite a proposed "renal sparing effect" of sulindac). Hypersensitivity has been implicated in some forms of sulindac-induced renal toxicity.[Ref]


Dermatologic side effects have included rash (3% to 9%), pruritus (1% to 3%), alopecia, photosensitivity, fixed-drug eruption, stomatitis, sore or dry mucous membranes, Stevens-Johnson syndrome, toxic epidermal necrolysis, and rare cases of fulminant necrotizing fasciitis.[Ref]

Nervous system

Underlying connective tissue disease, such as systemic lupus erythematosus, may be a predisposing factor for the development of sulindac-induced aseptic meningitis.[Ref]

Nervous system side effects including aseptic meningitis, paresthesia, encephalopathy, vertigo, insomnia, somnolence, convulsions, and syncope have been reported in greater than 1% of patients. Peripheral neuropathy has been reported rarely. Dizziness and headache have also been reported.[Ref]


Psychiatric side effects have included rare cases of reversible psychotic behavior, irritability, obsessiveness, depression, and visual and auditory hallucinations.[Ref]


Cardiovascular side effects have included palpitations and congestive heart failure, especially in patients with marginal cardiac function. Elevated blood pressure has also been reported.[Ref]

Nonsteroidal anti-inflammatory drugs (NSAIDs) may elevate blood pressure and increase the risk for the initiation of antihypertensive therapy. Furthermore, NSAIDs may antagonize the blood pressure lowering effect of antihypertensive medications in patients already being treated with antihypertensive drugs.[Ref]


Endocrine side effects have been reported rarely. These have included a case report of reversible gynecomastia.[Ref]


Metabolic side effects have included hyperkalemia, probably secondary to sulindac-induced hyporeninemic hypoaldosteronism.[Ref]


Musculoskeletal side effects have included muscle weakness.


1. Lilly E "Pancreatitis after administration of sulindac." JAMA 246 (1981): 2680

2. Siefkin AD "Sulindac and pancreatitis." Ann Intern Med 93 (1980): 932-3

3. Zygmunt DJ, Williams HJ, Bienz SR "Acute pancreatitis associated with long-term sulindac therapy." West J Med 144 (1986): 461-2

4. Levine MS, Rothstein RD, Laufer I "Giant esophageal ulcer due to clinoril." Am J Roentgenol 156 (1991): 955-6

5. Spirnak JP, Monahan DW "Colonic diaphragms associated with long-term use of nonsteroidal antiinflammatory drugs." AJR Am J Roentgenol 160 (1993): 1148-9

6. Detlefs RL "Drug-induced pancreatitis presenting as subcutaneous fat necrosis." J Am Acad Dermatol 13 (1985): 305-7

7. Lerche A, Vyberg M, Kirkegaard E "Acute cholangitis and pancreatitis associated with sulindac (clinoril)." Histopathology 11 (1987): 647-53

8. Hyson CP, Kazakoff MA "A severe multisystem reaction to sulindac." Arch Intern Med 151 (1991): 387-8

9. Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91

10. Goldstein J, Laskin DA, Ginsberg GH "Sulindac associated with pancreatitis." Ann Intern Med 93 (1980): 151

11. Ebel DL, Shih WJ, Rhymer AR "A multi-centre, double-blind randomized study to assess the efficacy and tolerance of sulindac versus placebo in the symptomatic treatment of patients with upper res." Curr Med Res Opin 9 (1985): 666-75

12. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.

13. Klein SM, Khan MA "Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy." J Rheumatol 10 (1983): 513-3

14. Tokumine F, Sunagawa T, Shiohira Y, Nakamoto T, Miyazato F, Muto Y "Drug-associated cholelithiasis: A case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones." Am J Gastroenterol 94 (1999): 2285-8

15. Gallanosa AG, Spyker DA "Sulindac hepatotoxicity: a case report and review." Clin Toxicol 23 (1985): 205-38

16. Dhand AK, LaBrecque DR, Metzger J "Sulindac (clinoril) hepatitis." Gastroenterology 80 (1981): 585-6

17. Whittaker SJ, Amar JN, Wanless IR, Heathcote J "Sulindac hepatotoxicity." Gut 23 (1982): 875-7

18. Daniele B, Pignata S, D'Agostino L, et al "Sulindac-induced severe hepatitis." Am J Gastroenterol 83 (1988): 1429-31

19. Giroux Y, Moreau M, Kass TG "Cholestatic jaundice caused by sulindac." Can J Surg 25 (1982): 334-5

20. Wood LJ, Mundo F, Searle J, Powell LW "Sulindac hepatotoxicity: effects of acute and chronic exposure." Aust N Z J Med 15 (1985): 397-401

21. Park GD, Spector R, Headstream T, Goldberg M "Serious adverse reactions associated with sulindac." Arch Intern Med 142 (1982): 1292-4

22. Jett GK, Wilson E "Anaphylactic reaction associated with sulindac." Ann Emerg Med 13 (1984): 462-4

23. Burrish GF, Kaatz BL "Sulindac-induced anaphylaxis." Ann Emerg Med 10 (1981): 154-5

24. Fein M "Sulindac and pneumonitis." Ann Intern Med 95 (1981): 245

25. Sprung DJ "Sulindac causing a hypersensitivity reaction with peripheral and mediastinal lymphadenopathy." Ann Intern Med 97 (1982): 564

26. Levites R, Hafitz G, Kirubakaran M "Febrile reaction to sulindac." JAMA 246 (1981): 213-4

27. Shojania AM, Rusen SD "Thrombocytopenia secondary to sulindac therapy." Can Med Assoc J 125 (1981): 1313

28. Romeril KR, Duke DS, Hollings PE "Sulindac induced agranulocytosis and bone marrow culture." Lancet 2 (1981): 523

29. Anderson RJ "Severe reaction associated with sulindac administration." N Engl J Med 300 (1979): 735-6

30. Andrews R, Russell N "Aplastic anaemia associated with a non-steroidal anti-inflammatory drug: relapse after exposure to another such drug." Br Med J 301 (1990): 38

31. Miller JL "Marrow aplasia and sulindac." Ann Intern Med 92 (1980): 129

32. Angeles ML, Reid ME, Yacob UA, Cash KL, Fetten JV "Sulindac-induced immune hemolytic anemia." Transfusion 34 (1994): 255-8

33. Morris EL, Hochberg MC, Dorsch CA "Agranulocytosis and sulindac." Arthritis Rheum 24 (1981): 752-3

34. Sanz MA, Martinez JA, Gomis F, Garcia-Borras JJ "Sulindac-induced bone marrow toxicity." Lancet 2 (1980): 802-3

35. Hynd RF, Klofkorn RW "Neutropenia and pseudomonas septicemia after sulindac therapy: case report." Mil Med 147 (1982): 768-9

36. Stambaugh JE Jr, Gordon RL, Geller R "Leukopenia and thrombocytopenia secondary to clinoril therapy." Lancet 2 (1980): 594

37. Johnson FP Jr, Hamilton HE, Liesch MR "Immune hemolytic anemia associated with sulindac." Arch Intern Med 145 (1985): 1515-6

38. Rosenbaum JT, O'Connor M "Thrombocytopenia associated with sulindac." Arthritis Rheum 24 (1981): 753-4

39. Bennett L, Schlossman R, Rosenthal J, et al "Aplastic anemia and sulindac." Ann Intern Med 92 (1980): 874

40. Karachalios GN, Parigorakis JG "Thrombocytopenia and sulindac." Ann Intern Med 104 (1986): 128

41. de Crespigny PJ, Becker GJ, Ihle BU, et al "Renal failure and nephrotic syndrome associated with sulindac." Clin Nephrol 30 (1988): 52-5

42. Turner GA, Walker RJ, Bailey RR, et al "Sulindac-induced acute interstitial nephritis." N Z Med J 97 (1984): 239-40

43. Perneger TV, Whelton PK, Klag MJ "Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs." N Engl J Med 331 (1994): 1675-9

44. Whelton A, Bender W, Vaghaiwalla F, et al "Sulindac and renal impairment." JAMA 249 (1983): 2892-3

45. Lomvardias S, Pinn VW, Wadhwa ML, et al "Nephrotic syndrome associated with sulindac." N Engl J Med 304 (1981): 424

46. Bunning RD, Barth WF "Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug." JAMA 248 (1982): 2864-7

47. Berg KJ, Talseth T "Acute renal effects of sulindac and indomethacin in chronic renal failure." Clin Pharmacol Ther 37 (1985): 447-52

48. Cangiano JL, Figueroa J, Palmer R "Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis." Clin Ther 21 (1999): 503-12

49. Bruce DR, Odom RB "Fixed drug eruption to sulindac." Cutis 38 (1986): 323-4

50. Small RE, Garnett WR "Sulindac-induced toxic epidermal necrolysis." Clin Pharm 7 (1988): 766-71

51. Levitt L, Pearson RW "Sulindac-induced Stevens-Johnson toxic epidermal necrolysis syndrome." JAMA 243 (1980): 1262-3

52. Reinertsen JL "Unusual pernio-like reaction to sulindac." Arthritis Rheum 24 (1981): 1215

53. Husain Z, Runge LA, Jabbs JM, Hyla JA "Sulindac-induced Stevens-Johnson syndrome: report of 3 cases." J Rheumatol 8 (1981): 176-9

54. Neufeld MY, Korczyn AD "Encephalopathy associated with sulindac." Hum Toxicol 5 (1986): 55

55. Ballas ZK, Donta ST "Suindac-induced aseptic meningitis." Arch Intern Med 142 (1982): 165-6

56. Sandyk R, Gillman MA "Acute exacerbation of Parkinson's disease with sulindac." Ann Neurol 17 (1985): 104-5

57. Von Reyn CF "Recurrent aseptic meningitis due to sulindac." Ann Intern Med 99 (1983): 343-4

58. Lorino GD, Hardin JG Jr "Sulindac-induced meningitis in mixed connective tissue disease." South Med J 73 (1983): 1185-7

59. Lending RE, Buchsbaum HW "Hypersensitivity reaction to sulindac (clinoril)." Arch Intern Med 144 (1984): 2259-60

60. Greenberg GN "Recurrent sulindac-induced aseptic meningitis in a patient tolerant to other nonsteroidal anti-inflammatory drugs." South Med J 81 (1988): 1463-4

61. Sabet-Sharghi F, Camara EG, Stagno S "Auditory and visual hallucinations associated with sulindac: focus on prostaglandin synthesis and psychotic symptoms." Psychosomatics 31 (1990): 461-2

62. Kruis R, Barger R "Paranoid psychosis with sulindac." JAMA 243 (1980): 1420

63. Thornton TL "Delirium associated with sulindac." JAMA 243 (1980): 1630-1

64. Easton PA, Koval A "Hypertensive reaction with sulindac." Can Med Assoc J 122 (1980): 1273-4

65. Johnson AG, Nguyen TV, Day RO "Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis." Ann Intern Med 121 (1994): 289-300

66. Gurwitz JH, Avron J, Bohn RL, Glynn RJ, Monane M, Mogun H "Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy." JAMA 272 (1994): 781-6

67. Kapoor A "Reversible gynecomastia associated with sulindac therapy." JAMA 250 (1983): 2284-5

68. Nesher G, Zimran A, Hershko C "Hyperkalemia associated with sulindac therapy." J Rheumatol 13 (1986): 1084-5

Not all side effects for Clinoril may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.